Webinar: An Informal Conversation with Aspen Neuroscience | Tuesday, May 11, 2021 | 5:00-7:00pm PDT

A Summit Webinar: (no CME credits)
An informal presentation and discussion with LIVE Q&A

Topics include:
Autologous Dopamine Neuron Replacement Therapy
Updates on the Summit-launched research project
Report on progress towards FDA approved clinical trials
(Content subject to change)

  • MDs, PAs, RNs
    NO CME Credits available for this event
  • LIVE Webinar
  • Registration Fee: FREE
  • Panel discussion with LIVE Q&A following Presentations
  • Physicians, Patients, Researchers, Students,
    – Everyone is WELCOME! 

Featured Guest Speakers:


Damien
McDevitt, Ph.D.

CEO Aspen Neuroscience / Board Director

Damien is an accomplished global strategist and distinguished leader in the Biotech and Pharmaceutical industry sectors. He is recognized for his vision, strategic planning, and corporate development.  His track record includes establishing, growing, and turning around businesses and completing more than 75 diverse transactions over two decades.  He has held multiple executive leadership roles in Biotech and Big Pharma where he has driven strategic expansion in the U.S., Europe, and Asia, significantly grown top line revenues, and executed a biotech company turn around.  Damien is highly qualified as a board director having been on the Aspen Neurosciences, Akcea and Biocom boards.

Damien is currently President and CEO of Aspen Neurosciences, an autologous cell therapy company focused on neurological diseases beginning with Parkinson’s disease. Before Aspen, Damien was CEO at Akcea where he transitioned from board member to CEO and inherited a struggling business.  He rebuilt the management team and board and introduced a strong culture of performance and accountability. He was credited with turning the business around with excellent 2020 results and leading the company through a successful sale and integration into Ionis. 

Before joining Akcea, Damien was Chief Business Officer and Executive Team Member, at Ionis Pharmaceuticals where he oversaw corporate development, investor relations, corporate communications, alliance management, and competitive intelligence functions, and served as a board member of Akcea. He completed multiple out-licensing deals, led plans for commercializing wholly owned medicines, and led the team that successfully rebranded the company.
Previously, Damien was Senior Vice President Corporate Development and Executive Team Member at Acadia Pharmaceuticals where he led the team that in-licensed trofinetide (Phase 3) for Rett syndrome, building a second product franchise for the company and an entrée into the rare disease space. 

Earlier in his career, Damien held increasingly responsible leadership positions at GlaxoSmithKline Pharmaceuticals, including Vice President, Head of Business Development for Extended Therapy Areas and Business Development Asia, and Head of the R&D West Coast Innovation Center.  During his tenure at GSK as part of the GSK/Avalon collaboration, he established seven single-asset biotech companies under option for GSK to acquire.  He established the Altius Institute in Seattle (translational regulomics) and completed ~60 deals. 

Damien is an author of 70 scientific publications and published patents.  He has a PhD in Microbiology and a BA degree in Microbiology, both from Trinity College in Dublin, Ireland.

 

Ed Wirth, M.D., Ph.D.

CMO, Aspen Neuroscience 

Dr. Edward Wirth, III, completed the M.D./Ph.D. program at the University of Florida (UF) in 1994. He elected to remain at UF to conduct postdoctoral research, and subsequently joined the faculty there in 1996. From 1997 to 2002, Dr. Wirth led the UF team that performed the first human embryonic spinal cord transplant in the United States. This pilot study demonstrated the feasibility and safety of implanting embryonic spinal cord cells into patients with post-traumatic syringomyelia (a complication to, spinal cord injury). From 2002 to 2000, Dr. Wirth held academic appointments at Rush Presbyterian St. Luke’s Medical Center and at the University of Chicago. From2004-2011, he served as Medical Director for Regenerative Medicine at Geron Corporation, where he led the world’s first clinical trial of a human embryonic stem cell (hESC)-derived product. He subsequently served as Chief Science Officer at InVivo Therapeutics from 2011-2012.

In 2013, he joined several former Geron colleagues at Asterias Biotherapeutics, which had acquired the stem cell assets of Geron. He served as Asterias’ Chief Translational Officer from 2013-2015 and Chief Medical Officer from 2015-2019. At Asterias he led the expansion and completion of the former Geron clinical trial, which demonstrated the initial clinical safety and activity of OPC1 (formerly GRNOPC1 & AST-OPC1), which contains hESC-derived oligodendrocyte progenitor cells (OPCs), in patients with subacute spinal cord injuries. He next served as Chief Medical Officer at Lineage Cell Therapeutics (formerly BioTime), which acquired Asterias in March 2019. 

Dr. Wirth joined Aspen Neuroscience as Chief Medical Officer in January, 2020.

 

Moderator:  Jeanne F. Loring, Ph.D.

Board Director & Chief Science Officer,
Summit for Stem Cell Foundation

Jeanne F. Loring is the Professor Emeritus at the Scripps Research Institute where she was founding Director of the Center for Regenerative Medicine. She is also founder of two stem cell-based biotechnology companies, Arcos Bioscience (now part of Viacyte) and Aspen Neuroscience, a biotechnology company developing a neuron replacement therapy for Parkinson disease. Dr. Loring has more than 30 years of experience in both biotechnology and academic research, focusing on stem cells, genomics, embryology and neurobiology. She holds five patents on stem cells and genomics, and has published more than 100 research articles in scientific journals that have been cited in scientific publications more than 14,000 times. She serves on both scientific advisory and bioethics boards, and advises governmental and private granting agencies in several countries. Through her laboratory courses, she has trained more than 400 scientists in stem cell technology.In addition to her work on Parkinson disease, Dr. Loring investigates multiple sclerosis and autism, and works with the San Diego Zoo Institute for Conservation Research in an effort to rescue the Northern white rhinoceros from extinction using stem cell technology. She is also involved in a project on the International Space Station to study neurogenerative disease.

Dr. Loring is an advocate for patients and an outspoken critic of stem cell clinics that operate outside of ethical or scientific oversight. She speaks out against unregulated stem cell therapies that have caused severe injuries and even death, and the clinics who convince desperately ill patients to pay for treatments that are not effective.

Refund Policy

If you are unable to attend a LIVE webinar, you may cancel up to the scheduled time of the event and receive a full refund. No refunds or exchanges for On-Demand Recoded Webinars. (Not yet available.) Refunds or exchanges for a LIVE webinar will not be given for no shows. As an alternative to a refund, you can substitute a registration for a future live webinar or have your fee converted to a tax deductible donation.

You must contact [email protected] to request a refund or move your registration to another webinar or to a donation. Cancelling your registration through GoToWebinar will NOT process a refund – you MUST contact Summit for Stem Cell Foundation at [email protected].

In the rare event that a webinar is cancelled or postponed due to unanticipated circumstances, registrants will be notified immediately and given the opportunity to either transfer their registration to another webinar or obtain a refund.

This policy supersedes all other policies regarding the LIVE CME Webinar series.